MX389613B - Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal. - Google Patents

Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.

Info

Publication number
MX389613B
MX389613B MX2018014081A MX2018014081A MX389613B MX 389613 B MX389613 B MX 389613B MX 2018014081 A MX2018014081 A MX 2018014081A MX 2018014081 A MX2018014081 A MX 2018014081A MX 389613 B MX389613 B MX 389613B
Authority
MX
Mexico
Prior art keywords
trigeminal neuralgia
carbamate compound
prevent
pharmaceutical composition
treat trigeminal
Prior art date
Application number
MX2018014081A
Other languages
English (en)
Spanish (es)
Other versions
MX2018014081A (es
Inventor
Han Ju Yi
Min Jae Jo
Sun Gwan Hwang
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2018014081A publication Critical patent/MX2018014081A/es
Publication of MX389613B publication Critical patent/MX389613B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2018014081A 2016-05-19 2017-05-18 Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal. MX389613B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160061386 2016-05-19
PCT/KR2017/005172 WO2017200317A1 (ko) 2016-05-19 2017-05-18 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (2)

Publication Number Publication Date
MX2018014081A MX2018014081A (es) 2019-09-02
MX389613B true MX389613B (es) 2025-03-20

Family

ID=60325324

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014081A MX389613B (es) 2016-05-19 2017-05-18 Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.

Country Status (14)

Country Link
US (2) US11207295B2 (cg-RX-API-DMAC7.html)
EP (1) EP3459542B1 (cg-RX-API-DMAC7.html)
JP (1) JP6960415B2 (cg-RX-API-DMAC7.html)
KR (1) KR102421013B1 (cg-RX-API-DMAC7.html)
CN (1) CN109310669B (cg-RX-API-DMAC7.html)
AU (1) AU2017267160B2 (cg-RX-API-DMAC7.html)
CA (1) CA3024284C (cg-RX-API-DMAC7.html)
DK (1) DK3459542T3 (cg-RX-API-DMAC7.html)
ES (1) ES2887338T3 (cg-RX-API-DMAC7.html)
MX (1) MX389613B (cg-RX-API-DMAC7.html)
PL (1) PL3459542T3 (cg-RX-API-DMAC7.html)
PT (1) PT3459542T (cg-RX-API-DMAC7.html)
RU (1) RU2751504C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017200317A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3035674T3 (en) 2016-12-14 2025-09-08 Sk Biopharmaceuticals Co Ltd Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease
CA3112166A1 (en) * 2018-09-21 2020-03-26 Sk Biopharmaceuticals Co., Ltd. Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
CA3116195A1 (en) * 2018-10-19 2020-04-23 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
DE2628420A1 (de) * 1976-06-24 1978-01-05 Bayer Ag 1-acyloxy-2-imidazolyl-1-phenyl- aethane, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide und nematizide
EA002401B1 (ru) * 1996-12-31 2002-04-25 Джи Пи Ай Нил Холдингс, Инк. N-связанные мочевины и карбаматы сложных гетероциклических тиоэфиров
MXPA03007721A (es) * 2001-02-27 2004-11-12 Johnson & Johnson Compuesto de carbamato para su uso en el tratamiento del dolor.
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
JP4227121B2 (ja) * 2005-06-08 2009-02-18 独立行政法人科学技術振興機構 神経因性疼痛治療剤
MY155662A (en) * 2009-06-22 2015-11-13 Sk Biopharmaceuticals Co Ltd Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US20130252924A1 (en) * 2010-11-11 2013-09-26 Akron Molecules Gmbh Compounds and Methods for Treating Pain
MX368735B (es) * 2014-05-09 2019-10-14 Tecnimede Sociedade Tecnico Medicinal S (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.

Also Published As

Publication number Publication date
EP3459542A4 (en) 2020-01-08
DK3459542T3 (da) 2021-09-13
CA3024284C (en) 2024-01-23
JP2019516722A (ja) 2019-06-20
AU2017267160A1 (en) 2018-12-13
CN109310669A (zh) 2019-02-05
EP3459542B1 (en) 2021-06-30
CN109310669B (zh) 2022-02-22
JP6960415B2 (ja) 2021-11-05
US20220087976A1 (en) 2022-03-24
PT3459542T (pt) 2021-08-24
ES2887338T3 (es) 2021-12-22
EP3459542A1 (en) 2019-03-27
RU2018144784A3 (cg-RX-API-DMAC7.html) 2020-08-11
CA3024284A1 (en) 2017-11-23
AU2017267160B2 (en) 2022-11-10
KR102421013B1 (ko) 2022-07-14
PL3459542T3 (pl) 2021-12-27
BR112018073556A2 (pt) 2019-03-19
MX2018014081A (es) 2019-09-02
RU2751504C2 (ru) 2021-07-14
RU2018144784A (ru) 2020-06-19
US11207295B2 (en) 2021-12-28
WO2017200317A1 (ko) 2017-11-23
US20190175555A1 (en) 2019-06-13
KR20170131241A (ko) 2017-11-29

Similar Documents

Publication Publication Date Title
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2023002004A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
NZ752250A (en) Compounds, devices, and uses thereof
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
MX394245B (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
JOP20190186A1 (ar) مركب كينازولين
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
WO2015200680A8 (en) Prmt5 inhibitors and uses thereof
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MY196576A (en) Amino Pyrimidine SSAO Inhibitors
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
MX388175B (es) Compuestos terapéuticos y métodos para utilizarlos
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
MX389613B (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
EA201891240A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.